Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
=== Medical use === PABA and its salts are used in nutritional epidemiological studies to assess the completeness of 24-hour urine collection for the determination of urinary sodium, potassium, or nitrogen levels. The potassium salt (potassium paraaminobenzoate, "aminobenzoate potassium") is used as a drug against fibrotic skin disorders, such as Peyronie's disease, under the brand name Potaba. There is a lack of strong evidence. It is believed to work by inhibiting fibroblast glycosaminoglycan secretion and stabilizing monoamine oxidase A activity. PABA is also occasionally used in pill form by sufferers of irritable bowel syndrome to treat its associated gastrointestinal symptoms. PABA derivatives have also been proposed to function as acetylcholinesterase inhibitors in diseases that cause deficient cholinergic systems, such as Alzheimer's disease.
=== 1947 === January 1: The American and British zones of control in Germany are united to form the Bizone, also known as Bizonia. February 10: Establishment of the neutral state Free Territory of Trieste. February 25: Prussia was de jure abolished. February 27: The February 28 incident begins in Taiwan lasting until mid-March. March 7: Paraguayan Civil War begins. March 12: President Harry Truman announces the Truman Doctrine starting with the giving of aid to Greece and Turkey in order to prevent them from falling into the Soviet sphere. April 16: Bernard Baruch, in a speech given during the unveiling of his portrait in the South Carolina House of Representatives, coins the term "Cold War" to describe relations between the United States and the Soviet Union. May 22: US extends $400 million of military aid to Greece and Turkey, signalling its intent to contain communism in the Mediterranean. June 5: Secretary of State George Marshall outlines plans for a comprehensive program of economic assistance for the war-ravaged countries of Western Europe. It would become known throughout the world as the Marshall Plan. July 11: The US announces new occupation policies in Germany.
== Applications == PEDOT:PSS has the highest efficiency among conductive organic thermoelectric materials (ZT~0.42) and thus can be used in flexible thermoelectric generators. Yet its largest application is as a transparent, conductive polymer with high ductility. For example, AGFA coats 200 million photographic films per year with a thin, extensively-stretched layer of virtually transparent and colorless PEDOT:PSS as an antistatic agent to prevent electrostatic discharges during production and normal film use, independent of humidity conditions, and as electrolyte in polymer electrolytic capacitors. PEDOT:PSS is commonly used in organic light emitting diode (OLED) and organic solar cell for hole injection or hole extraction to improve carrier transport. If organic compounds, including high boiling solvents like methylpyrrolidone, dimethyl sulfoxide, sorbitol, ionic liquids and surfactants, are added conductivity increases by many orders of magnitude. This makes it also suitable as a transparent electrode, for example in touchscreens, organic light-emitting diodes, flexible organic solar cells and electronic paper to replace the traditionally used indium tin oxide (ITO). Owing to the high conductivity (up to 4600 S/cm), it can be used as a cathode material in capacitors replacing manganese dioxide or liquid electrolytes. It is also used in organic electrochemical transistors.
=== Carbamylated proteins === Within nature carbon dioxide can bind with neutral amine groups to form a carbamate. This post-translational modification is known as carbamylation, and is known to occur on several important proteins. The N-terminal amino groups of valine residues in the α- and β-chains of deoxyhemoglobin exist as carbamates. They help to stabilise the protein when it becomes deoxyhemoglobin, and increases the likelihood of the release of remaining oxygen molecules bound to the protein. This stabilizing effect should not be confused with the Bohr effect (an indirect effect caused by carbon dioxide). The ε-amino groups of the lysine residues in urease and phosphotriesterase also feature carbamate.
The Enzyme Function Initiative (EFI) is a large-scale collaborative project aiming to develop and disseminate a robust strategy to determine enzyme function through an integrated sequence–structure-based approach. The project was funded in May 2010 by the National Institute of General Medical Sciences as a Glue Grant which supports the research of complex biological problems that cannot be solved by a single research group. The EFI was largely spurred by the need to develop methods to identify the functions of the enormous number proteins discovered through genomic sequencing projects.
Sources: en.wikipedia.org
=== Insulin access and innovation === In response to rising insulin costs and research showing that many people with diabetes are skipping or rationing their insulin, Breakthrough T1D has advocated for insurance companies to provide better health coverage for those living with type 1 diabetes, including making out-of-pocket costs for insulin and other vital diabetes tools more predictable and reasonable. The aim of this advocacy is to ensure people have the freedom to choose treatment strategies that are appropriate for them, and to cover artificial pancreas/automated insulin delivery systems. In response to escalating insulin affordability issues, Breakthrough T1D partnered with nonprofit drug maker Civica to manufacture insulin that will cost $30 a vial, regardless of a patient's insurance provider. Civica insulin is expected to be available to the public in 2025. Breakthrough T1D also advocates for passage of the INSULIN Act, which caps cost-sharing under private health insurance for a month's supply of selected insulin products at $35 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2025.
Still, during the Soviet era, Jews were encouraged to admire Cossacks as the antitheses of the "parasitic" and "feeble dwellers of the shtetl." A number of Yiddish writers, including Khaim Melamud, Shmuel Gordon, Viktor Fink, and Shmuel Godiner, presented fictionalized accounts of peaceful Jewish-Cossack coexistence, while efforts were made by the pro-Soviet press to present Khmelnytsky as a heroic figure and Cossacks as liberators from the Nazis. Historiography interprets Cossackdom in imperial and colonial terms. In Ukraine, where Cossackdom represents historical and cultural heritage, some people have begun attempting to recreate the images of Ukrainian Cossacks. Traditional Ukrainian culture is often tied in with the Cossacks, and the Ukrainian government actively supports these attempts. The traditional Cossack bulava serves as a symbol of the Ukrainian presidency, and the island of Khortytsia, the origin and center of the Zaporozhian Sich, has been restored. The video game Cossacks: European Wars is a Ukrainian-made game series influenced by Cossack culture. Cossacks are also mentioned outside Europe. The Japanese anime The Doraemons, part of the larger Doraemon anime series, has a Cossack character, Dora-nichov, who is from Russia.
Cephalopods, as the name implies, have muscular appendages extending from their heads and surrounding their mouths. These are used in feeding, mobility, and even reproduction. In coleoids they number eight or ten. Decapods such as cuttlefish and squid have five pairs. The longer two, termed "tentacles", are actively involved in capturing prey; they can lengthen rapidly (in as little as 15 milliseconds). In giant squid, they may reach a length of 8 metres. They may terminate in a broadened, sucker-coated club. The shorter four pairs are termed arms, and are involved in holding and manipulating the captured organism. They too have suckers, on the side closest to the mouth; these help to hold onto the prey. Octopods only have four pairs of sucker-coated arms, as the name suggests, though developmental abnormalities can modify the number of arms expressed. The tentacle consists of a thick central nerve cord (which must be thick to allow each sucker to be controlled independently) surrounded by circular and radial muscles. Because the volume of the tentacle remains constant, contracting the circular muscles decreases the radius and permits the rapid increase in length. Typically, a 70% lengthening is achieved by decreasing the width by 23%. The shorter arms lack this capability. The size of the tentacle is related to the size of the buccal cavity; larger, stronger tentacles can hold prey as small bites are taken from it; with more numerous, smaller tentacles, prey is swallowed whole, so the mouth cavity must be larger.
The S&P SmallCap 600 (S&P 600) stock market index, maintained by S&P Dow Jones Indices, comprises the common stocks of 600 small-cap, mostly American, companies. Although called the "S&P 600", the index contains 603 stocks because it includes two share classes of stock from three of its component companies (Central Garden & Pet Company, Clearway Energy and Under Armour). Stocks here are cross referenced with the following index funds to compose the list:
Sources: en.wikipedia.org
, where distance is the direct (not logarithmic) distance in number of decades or "octaves" to the right the mass concentration is found. To translate from mass to molar concentration, the dividend (molar mass and the divisor (1000) in the division change places, or, alternatively, distance to right is changed to distance to left. Substances with a molar mass around 1000g/mol (e.g. thyroxine) are almost vertically aligned in the mass and molar images. Adrenocorticotropic hormone, on the other hand, with a molar mass of 4540, is 0.7 decades to the right in the mass image. Substances with molar mass below 1000g/mol (e.g. electrolytes and metabolites) would have "negative" distance, that is, masses deviating to the left. Many substances given in mass concentration are not given in molar amount because they haven't been added to the article. The diagram above can also be used as an alternative way to convert any substance concentration (not only the normal or optimal ones) from molar to mass units and vice versa for those substances appearing in both scales, by measuring how much they are horizontally displaced from one another (representing the molar mass for that substance), and using the same distance from the concentration to be converted to determine the equivalent concentration in terms of the other unit. For example, on a certain monitor, the horizontal distance between the upper limits for parathyroid hormone in pmol/L and pg/mL may be 7 cm, with the mass concentration to the right.
== Boiling == After mashing, the beer wort is boiled with hops (and other flavourings if used) in a large tank known as a "copper" or brew kettle – though historically the mash vessel was used and is still in some small breweries. The boiling process is where chemical reactions take place, including sterilisation of the wort to remove unwanted bacteria, releasing of hop flavours, bitterness and aroma compounds through isomerisation, stopping of enzymatic processes, precipitation of proteins, and concentration of the wort. Finally, the vapours produced during the boil volatilise off-flavours, including dimethyl sulphide precursors. The boil is conducted so that it is even and intense – a continuous "rolling boil". The boil on average lasts between 45 and 90 minutes, depending on its intensity, the hop addition schedule, and volume of water the brewer expects to evaporate. At the end of the boil, solid particles in the hopped wort are separated out, usually in a vessel called a "whirlpool".
Feathers are a feature characteristic of birds (though also present in some dinosaurs not currently considered to be true birds). They facilitate flight, provide insulation that aids in thermoregulation, and are used in display, camouflage, and signalling. There are several types of feathers, each serving its own set of purposes. Feathers are epidermal growths attached to the skin and arise only in specific tracts of skin called pterylae. The distribution pattern of these feather tracts (pterylosis) is used in taxonomy and systematics. The arrangement and appearance of feathers on the body, called plumage, may vary within species by age, social status, and sex. Plumage is regularly moulted; the standard plumage of a bird that has moulted after breeding is known as the "non-breeding" plumage, or—in the Humphrey–Parkes terminology—"basic" plumage; breeding plumages or variations of the basic plumage are known under the Humphrey–Parkes system as "alternate" plumages. Moulting is annual in most species, although some may have two moults a year, and large birds of prey may moult only once every few years. Moulting patterns vary across species. In passerines, flight feathers are replaced one at a time with the innermost primary being the first. When the fifth of sixth primary is replaced, the outermost tertiaries begin to drop. After the innermost tertiaries are moulted, the secondaries starting from the innermost begin to drop and this proceeds to the outer feathers (centrifugal moult). The greater primary coverts are moulted in synchrony with the primary that they overlap.
The Office of National Drug Control Policy of the United States estimates that only in that country, sales of narcotic drugs represent about 57,000 million dollars annually and most of these transactions are made in cash.
In 1977, eager to return to acting, Kidder read for the character of Lois Lane in Superman: The Movie, only one month before principal photography was scheduled to begin. Kidder was flown to England for screen tests. Upon meeting with director Richard Donner, Kidder tripped while walking into the room. Donner recalled: "I just fell in love with her. It was perfect, this clumsy [behavior]." She was ultimately cast in the role, which would become her most iconic. Filming lasted about 18 months. Superman was released during Christmas 1978 and was a major commercial success, grossing $300 million worldwide. She was deemed "most charming" by Vincent Canby in The New York Times. James Harwood of Variety said that she "plays perfectly off both of his [Reeve's] personalities and her initial double-entendre interview with Superman is wickedly coy, dancing round the obvious question any red-blooded girl might ask herself about such a magnificent prospect." Sonia Saraiya of Vanity Fair praised her ability to balance Lois's ditzy nature with her ambition and no-nonsense attitude, and wrote: "Kidder played a human woman who could believably both attract and deserve a man who is canonically perfect, with the physique of a Greek god and the moral compass of a saint." For the role, Kidder won the Saturn Award for Best Actress. After completing filming for Superman, Kidder starred as Kathy Lutz in the supernatural horror film The Amityville Horror (1979), which further cemented her status as one of Hollywood's leading ladies.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.